Table 5 Joint effect of HPV16 serology and the combined risk genotypes of TNF-α SNPs on risk of OSCC, stratified by age
Risk groups1 | HPV16 status | Patients | Controls | Adjusted OR (95% CI)2 | |||
|---|---|---|---|---|---|---|---|
(n = 325) | (n = 335) | ||||||
No. | % | No. | % | OSCC | SCCOP | ||
Young (aged < 50 years) | (n = 87) | (n = 87) | |||||
Low-risk group | − | 12 | 13.8 | 29 | 33.3 | 1.0 | 1.0 |
Medium-risk group | − | 19 | 21.8 | 35 | 40.2 | 1.2 (0.5 − 3.1) | 1.1 (0.3 − 4.5) |
High-risk group | − | 24 | 27.6 | 13 | 14.9 | 4.1 (1.5 − 11.5) | 5.5 (1.4 − 21.2) |
Low-risk group | + | 7 | 8.1 | 5 | 5.8 | 4.7 (1.1 − 19.7) | 10.1 (2.0 − 52.3) |
Medium-risk group | + | 9 | 10.3 | 3 | 3.5 | 8.9 (1.8 − 43.5) | 16.6 (2.9 − 6.1) |
High-risk group | + | 16 | 18.4 | 2 | 2.3 | 22.6 (4.2 − 121.3) | 50.7 (7.5 − 341.9) |
Older (aged ≥ 50 years) | (n = 238) | (n = 248) | |||||
Low-risk group | − | 49 | 20.6 | 52 | 21.0 | 1.0 | 1.0 |
Medium-risk group | − | 34 | 14.3 | 94 | 37.9 | 0.4 (0.2 − 0.7) | 0.4 (0.2 − 0.8) |
High-risk group | − | 87 | 36.6 | 70 | 28.2 | 1.3 (0.8 − 2.2) | 1.2 (0.6 − 2.3) |
Low-risk group | + | 20 | 8.4 | 8 | 3.2 | 2.5 (1.0 − 6.2) | 3.9 (1.4 − 10.6) |
Medium-risk group | + | 14 | 5.9 | 18 | 7.3 | 0.9 (0.4 − 1.9) | 1.6 (0.6 − 3.9) |
High-risk group | + | 34 | 14.3 | 6 | 2.4 | 5.7 (2.2 − 15.0) | 10.2 (3.6 − 28.4) |